已收盤 08-29 16:00:00 美东时间
+0.130
+1.07%
LENSAR (NASDAQ:LNSR) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.02) by 650 percent. This is a 67.39 percent increase over losses of $(0.46) per share from the same
08-07 19:28
(来源:CHC医疗传媒) 2025 年 8 月 5 日,全球眼科医疗巨头爱尔康(Alcon)宣布以 15 亿美元(约合107亿元人民币)收购纳斯达克上市公司...
08-07 14:30
LENSAR ( ($LNSR) ) has issued an update. On July 2, 2025, LENSAR, Inc. held a v...
07-03 04:17
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
06-03 04:01
LENSAR, Inc. announced that a majority of its independent board members granted 3,090 restricted stock units (RSUs) to 10 newly-hired non-executive employees as an inducement for joining the Company. The RSUs vest over four years, contingent on continued employment. LENSAR, a medical device company, specializes in developing advanced systems like the ALLY Robotic Cataract Laser System, which integrates AI for improved surgical outcomes and effici...
06-02 20:01
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.
05-30 01:28
LENSAR ( ($LNSR) ) just unveiled an update. On March 23, 2025, LENSAR, Inc. ent...
05-23 05:12
New activity is brewing for LENSAR ( ($LNSR) ). The company has submitted a For...
05-20 05:16
NEW YORK, May 16, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the ...
05-17 06:30
LENSAR (NASDAQ:LNSR) reported quarterly losses of $(2.32) per share which missed the analyst consensus estimate of $(0.21) by 1004.76 percent. This is a 1121.05 percent decrease over losses of $(0.19) per share from the
05-08 19:27